Literature DB >> 19254626

Multiple myeloma.

S Vincent Rajkumar.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19254626      PMCID： PMC2743983          DOI： 10.1016/j.currproblcancer.2009.01.001

Source DB:  PubMed          Journal:  Curr Probl Cancer        ISSN： 0147-0272            Impact factor:   3.187


× No keyword cloud information.
  236 in total

1.  [Clinical experiences with sarcolysin in neoplastic diseases].

Authors:  N BLOKHIN; L LARIONOV; N PEREVODCHIKOVA; L CHEBOTAREVA; N MERKULOVA
Journal:  Ann N Y Acad Sci       Date:  1958-04-24       Impact factor: 5.691

2.  The base of the proteasome regulatory particle exhibits chaperone-like activity.

Authors:  B C Braun; M Glickman; R Kraft; B Dahlmann; P M Kloetzel; D Finley; M Schmidt
Journal:  Nat Cell Biol       Date:  1999-08       Impact factor: 28.824

3.  Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants.

Authors:  G Tricot; J R Sawyer; S Jagannath; K R Desikan; D Siegel; S Naucke; S Mattox; D Bracy; N Munshi; B Barlogie
Journal:  J Clin Oncol       Date:  1997-07       Impact factor: 44.544

4.  High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.

Authors:  Jean-Paul Fermand; Sandrine Katsahian; Marine Divine; Veronique Leblond; Francois Dreyfus; Margaret Macro; Bertrand Arnulf; Bruno Royer; Xavier Mariette; Edouard Pertuiset; Coralie Belanger; Maud Janvier; Sylvie Chevret; Jean Claude Brouet; Philippe Ravaud
Journal:  J Clin Oncol       Date:  2005-11-07       Impact factor: 44.544

5.  A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS.

Authors:  Wee Joo Chng; Scott A Van Wier; Gregory J Ahmann; Jerry M Winkler; Syed M Jalal; Peter Leif Bergsagel; Marta Chesi; Mike C Trendle; Martin M Oken; Emily Blood; Kim Henderson; Rafael Santana-Dávila; Robert A Kyle; Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Philip R Greipp; Rafael Fonseca
Journal:  Blood       Date:  2005-05-26       Impact factor: 22.113

Review 6.  Solitary plasmacytoma of bone and asymptomatic multiple myeloma.

Authors:  M A Dimopoulos; L A Moulopoulos; A Maniatis; R Alexanian
Journal:  Blood       Date:  2000-09-15       Impact factor: 22.113

7.  A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma.

Authors:  Angelo Vacca; Roberto Ria; Domenico Ribatti; Fabrizio Semeraro; Valentin Djonov; Francesco Di Raimondo; Franco Dammacco
Journal:  Haematologica       Date:  2003-02       Impact factor: 9.941

8.  American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.

Authors:  James R Berenson; Bruce E Hillner; Robert A Kyle; Ken Anderson; Allan Lipton; Gary C Yee; J Sybil Biermann
Journal:  J Clin Oncol       Date:  2002-09-01       Impact factor: 44.544

9.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

10.  Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.

Authors:  Jerry A Katzmann; Raynell J Clark; Roshini S Abraham; Sandra Bryant; James F Lymp; Arthur R Bradwell; Robert A Kyle
Journal:  Clin Chem       Date:  2002-09       Impact factor: 8.327
View more
  23 in total

1.  The albumin and monoclonal protein ratio as prognostic marker for multiple myeloma in the era of novel agents.

Authors:  Katalin Kádár; Krisztina Wolf; Judit Tábori; István Karádi; Judit Várkonyi
Journal:  Pathol Oncol Res       Date:  2012-07       Impact factor: 3.201

2.  (11)C-acetate as a new biomarker for PET/CT in patients with multiple myeloma: initial staging and postinduction response assessment.

Authors:  Chieh Lin; Chi-Lai Ho; Shu-Hang Ng; Po-Nan Wang; Yenlin Huang; Yu-Chun Lin; Tzung-Chih Tang; Shu-Fan Tsai; Alain Rahmouni; Tzu-Chen Yen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-10-16       Impact factor: 9.236

Review 3.  NF-κB pathways in hematological malignancies.

Authors:  Chiara Gasparini; Claudio Celeghini; Lorenzo Monasta; Giorgio Zauli
Journal:  Cell Mol Life Sci       Date:  2014-01-14       Impact factor: 9.261

4.  Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.

Authors:  Deborah J Kuhn; Zuzana Berkova; Richard J Jones; Richard Woessner; Chad C Bjorklund; Wencai Ma; R Eric Davis; Pei Lin; Hua Wang; Timothy L Madden; Caimiao Wei; Veerabhadran Baladandayuthapani; Michael Wang; Sheeba K Thomas; Jatin J Shah; Donna M Weber; Robert Z Orlowski
Journal:  Blood       Date:  2012-08-29       Impact factor: 22.113

5.  Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity.

Authors:  Maria Vaiou; Evanthia Pangou; Panagiotis Liakos; Nikos Sakellaridis; George Vassilopoulos; Konstantinos Dimas; Christos Papandreou
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-16       Impact factor: 4.553

6.  An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.

Authors:  Ravi Vij; Michael Wang; Jonathan L Kaufman; Sagar Lonial; Andrzej J Jakubowiak; A Keith Stewart; Vishal Kukreti; Sundar Jagannath; Kevin T McDonagh; Melissa Alsina; Nizar J Bahlis; Frederic J Reu; Nashat Y Gabrail; Andrew Belch; Jeffrey V Matous; Peter Lee; Peter Rosen; Michael Sebag; David H Vesole; Lori A Kunkel; Sandra M Wear; Alvin F Wong; Robert Z Orlowski; David S Siegel
Journal:  Blood       Date:  2012-05-03       Impact factor: 22.113

7.  An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.

Authors:  Ravi Vij; David S Siegel; Sundar Jagannath; Andrzej J Jakubowiak; Alexander Keith Stewart; Kevin McDonagh; Nizar Bahlis; Andrew Belch; Lori A Kunkel; Sandra Wear; Alvin F Wong; Michael Wang
Journal:  Br J Haematol       Date:  2012-07-30       Impact factor: 6.998

8.  Bisphosphonate-induced osteoradionecrosis.

Authors:  Ruchi Bhuyan; Sanat Bhuyan; Rajat G Panigrahi; Antarmayee Panigrahi
Journal:  J Oral Maxillofac Pathol       Date:  2013-09

9.  Isolation of circulating plasma cells from blood of patients diagnosed with clonal plasma cell disorders using cell selection microfluidics.

Authors:  Joyce W Kamande; Maria A M Lindell; Małgorzata A Witek; Peter M Voorhees; Steven A Soper
Journal:  Integr Biol (Camb)       Date:  2018-02-19       Impact factor: 2.192

Review 10.  Glucocorticoids and Cancer.

Authors:  Miles A Pufall
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.